Although rare in occurrence, breast implant-associated anaplastic large-cell lymphoma recently found its way into the national news. Here, Pathology in Practice Science Editor Brian Nation compiles a selection of current research interest in this iatrogenic disease.
Breast Implant-Associated Anaplastic Large Cell Lymphoma: Where Hematology and Plastic Surgery Meet
Joks MM, Czernikiewicz K, Mazurkiewicz Ł et al. Clin Lymphoma Myeloma Leuk. 2024 Sep; 24 (9): e293–e300. doi: 10.1016/j.clml.2024.05.008.
Breast implant insertion for breast reconstruction or breast augmentation is a developing procedure, with high demand worldwide-being the second most common plastic surgery in the US as of 2022. Breast-implant-associated anaplastic large cell lymphoma (BIA-ALCL) is T-cell, non-Hodgkin lymphoma, typically CD30+, ALK–, presenting with fluid collection in the inner aspect of the peri-implant capsule in most patients, with the onset exceeding one-year after implantation. The mean time between breast implant insertion and BIA-ALCL development is seven to 10 years.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.